OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Global, regional and national trends in statin utilisation in high-income and low/middle-income countries, 2015–2020
Jenny S. Guadamuz, Andrew Shooshtari, Dima M. Qato
BMJ Open (2022) Vol. 12, Iss. 9, pp. e061350-e061350
Open Access | Times Cited: 23

Showing 23 citing articles:

Mortality and burden related with aortic aneurysms and dissections. The importance of information and education
Antonio V. Sterpetti, Raimondo Gabriele, Paolo Sapienza, et al.
Current Problems in Cardiology (2024) Vol. 49, Iss. 3, pp. 102384-102384
Open Access | Times Cited: 18

Statin-induced necrotising myositis with heart failure: a lesson in cautious prescribing of common drugs
M Perlman Jeffrey, Bryan Whelan
BMJ Case Reports (2025) Vol. 18, Iss. 2, pp. e263709-e263709
Closed Access | Times Cited: 1

Benefits and Risks Associated With Statin Therapy for Primary Prevention in Old and Very Old Adults
Wanchun Xu, A Lee, Cindy Lo Kuen Lam, et al.
Annals of Internal Medicine (2024) Vol. 177, Iss. 6, pp. 701-710
Closed Access | Times Cited: 9

The burden of hypercholesterolemia and ischemic heart disease in an ageing world
Angela Pirillo, Giuseppe Danilo Norata
Pharmacological Research (2023) Vol. 193, pp. 106814-106814
Open Access | Times Cited: 21

The effects of statins on mitochondria – the current state of knowledge
Małgorzata Belczyk, Małgorzata Knapik-Czajka, Anna Gawędzka, et al.
Farmacja Polska (2025) Vol. 80, Iss. 8, pp. 579-587
Open Access

Lipid-targeting antiviral strategies: current state and future perspectives
Ana-Belén Blázquez, Patricia Mingo‐Casas, Ernesto Quesada, et al.
Antiviral Research (2025), pp. 106103-106103
Closed Access

Determining cost-saving risk thresholds for statin use
Afschin Gandjour
PLoS ONE (2025) Vol. 20, Iss. 3, pp. e0318454-e0318454
Open Access

Uncovering Protein Prenylation in Th1 Cells: Novel Prenylation Sites and Insights into Statin and Farnesyltransferase Inhibition
Jana Koch, Alessandra Ruggia, Carina Beha, et al.
Research Square (Research Square) (2025)
Closed Access

The Global Burden of premature cardiovascular disease, 1990–2019
Hossam Lababidi, Pedro Rafael Vieira de Oliveira Salerno, Sojin Y. Wass, et al.
International Journal of Cardiology Cardiovascular Risk and Prevention (2023) Vol. 19, pp. 200212-200212
Open Access | Times Cited: 12

Triglyceride-glucose index, low-density lipoprotein levels, and cardiovascular outcomes in chronic stable cardiovascular disease: results from the ONTARGET and TRANSCEND trials
Bernhard Haring, Helmut Schumacher, Giuseppe Mancia, et al.
European Journal of Preventive Cardiology (2023) Vol. 31, Iss. 3, pp. 311-319
Closed Access | Times Cited: 11

Decoding the Intricacies of Statin-Associated Muscle Symptoms
Tara Fallah Rastegar, Imtiaz Ahmed Khan, Lisa Christopher‐Stine
Current Rheumatology Reports (2024) Vol. 26, Iss. 7, pp. 260-268
Closed Access | Times Cited: 2

GWAS breakthroughs: mapping the journey from one locus to 393 significant coronary artery disease associations
Rédouane Aherrahrou, Tobias Reinberger, Satwat Hashmi, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 13, pp. 1508-1530
Open Access | Times Cited: 2

Vascular disease and ischemic stroke in patients with atrial fibrillation: Temporal trends and age-related differences
Konsta Teppo, Elin Karlsson, Tuomas Kiviniemi, et al.
Atherosclerosis (2024), pp. 118590-118590
Open Access | Times Cited: 1

Statins in the Cause and Prevention of Cancer: Confounding by Indication and Mediation by Rhabdomyolysis and Phosphate Toxicity
Ronald B. Brown
Journal of Cardiovascular Development and Disease (2024) Vol. 11, Iss. 9, pp. 296-296
Open Access | Times Cited: 1

Myasthenia gravis following statin therapy: evidence from target trial emulation and self-controlled case series study
Wanchun Xu, Vincent Ka Chun Yan, Zhijuan Zhang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1

Outpatient atorvastatin use and severe COVID‐19 outcomes: A population‐based study
Irene Visos‐Varela, Maruxa Zapata‐Cachafeiro, Samuel Pintos‐Rodríguez, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 7
Open Access | Times Cited: 4

Are statins making older persons weaker? A discontinuation study of muscular side effects
Morten Bruun Korsholm, Thea Winther Pødenphanth, Sofie Kirstine Strømgaard, et al.
GeroScience (2023)
Open Access | Times Cited: 3

Cholesterol and Cholesterol-Lowering Medications in COVID-19—An Unresolved Matter
Thomas Grewal, Mai Khanh Linh Nguyen, Christa Buechler
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10489-10489
Open Access

Determining Cost-Saving Risk Thresholds for Statin Use
Afschin Gandjour
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access

Chemerin Levels in COVID-19 Are More Affected by Underlying Diseases than by the Virus Infection Itself
Vlad Pavel, Pablo Amend, Niklas Schmidtner, et al.
Biomedicines (2024) Vol. 12, Iss. 9, pp. 2099-2099
Open Access

Differential effects of OATP2B1 on statin accumulation and toxicity in a beta cell model
Jihoon Kwon, Michelle S. Kim, Christina Blagojevic, et al.
Toxicology Mechanisms and Methods (2023) Vol. 34, Iss. 2, pp. 130-147
Closed Access | Times Cited: 1

Page 1

Scroll to top